CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a biopharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen’s deep understanding of the human genome has enabled us to gain greater insight into the molecular basis of disease. The Company's therapeutics are based on novel drug targets that are believed to play a role in proven mechanisms underlying disease. CuraGen has translated this understanding into a pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes. The Company’s strategy remains focused on advancing its pipeline of promising therapeutics through clinical and preclinical development. History CuraGen was founded when the massive undertaking to sequence the human genome was just beginning. The Company's strategy was based on discovering novel ways to combat disease through an understanding of how genes and their resulting proteins function within the human genome. CuraGen developed an integrated genomics, proteomics, and bioinformatics technology platform that was used to analyze the human genome, disease models, and therapeutic candidates. This approach led to the identification of disease-related genes and therapeutic targets with the subsequent development of novel pharmaceutical products. Today, CuraGen remains one of the leading genomics-based pharmaceutical companies in the industry with a pipeline of protein, antibody, and small molecule therapeutics. The Company is headquartered in Branford, CT.

Contact Details: 322 East Main Street Branford CT 06405 United States of America Tel: (888) 436-6642 or (203) 481-1104 Fax: (203) 483-2552 Email: info@curagen.com WWW: www.curagen.com/

Loading...

Recent Publications by CuraGen:
A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. OBJECTIVE: To investigate the safety, pharmacokinetics (PK), binding...	19th August, 2008	CuraGen Corporation, Branford, CT 06405, USA.	Int J Clin Pharmacol Ther. 2008 May;46(5):236-44.
Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05)Reduces the Severity and Duration of Oral Mucositis. Oral mucositis (OM) is a treatment-limiting condition associated with...	17th July, 2008	CuraGen Corporation, Branford, CT.	Support Cancer Ther. 2005 Jan 1;2(2):122-7. DOI Direct Link
Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. PURPOSE: Velafermin (recombinant human fibroblast growth factor-20,...	4th July, 2008	CuraGen Corporation, Branford, Connecticut, USA.	Int J Radiat Biol. 2008 May;84(5):401-12. DOI Direct Link
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Histone deacetylase inhibitors (HDACi) represent a promising new class of...	2nd April, 2008	CuraGen Corporation, Branford, CT 06405, USA.	Int J Cancer. 2008 Mar 15;122(6):1400-10. DOI Direct Link
Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. PURPOSE: To investigate the pharmacological properties of the CR011-vcMMAE...	19th August, 2007	Department of Preclinical Development, CuraGen Corporation, 322 E. Main	Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35. Epub 2007 Jun 1. DOI Direct Link
→View more CuraGen research publications.

BioNews Results for CuraGen:
CuraGen acknowledges Nasdaq notice	Mass High Tech:  Sep 27 2008 1:15AM Matching: curagen
Molecular Insight names interim CEO	Mass High Tech:  Sep 27 2008 1:15AM Matching: curagen
CuraGen Corporation Receives Notification from NASDAQ	Pharma Live:  Sep 26 2008 12:22PM Matching: curagen
CuraGen Corporation Receives Notification from NASDAQ	TickerTech.com:  Sep 26 2008 1:14PM Matching: curagen
CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma	PipelineReview:  Sep 15 2008 4:17PM Matching: curagen
Promote your company here: BioNewsCast - Press Release Distribution	→View more CuraGen news.

CuraGen Patents:
US Patent No.	Title
6534291	Compositions and methods for fumonisin detoxification
6699967	Hepatoma-derived growth factor-like proteins, polynucleotides encoding them and methods of use
6750012	Method of identifying a psychotropic agent using differential gene expression
6753314	Protein-protein complexes and methods of using same
6822140	Compositions and methods for fumonisin detoxification
→View more CuraGen patents.

CuraGen (CRGN) Financial information Links from Barchart
CRGN Quote from from Barchart.com
CRGN Chart from from Barchart.com
CRGN Profile from from Barchart.com
CRGN Opinion from from Barchart.com
→View more CuraGen finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 17 individuals from CuraGen using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 491 times since April 2007, the link to the organisation's website has been followed 85 times

Recent Search Terms used to find this page: CURAGEN founded | Curagen address | Contact of CuraGen | Contact of CuraGen | Velafermin rhFGF-20 | Oncology Preclinical Development Department at CuraGen Corporation. | pharmaceutical companies in brandford ct | human genome branford ct | curagen | CURAGEN CORPORATION ct | .

Search for more companies in Branford

Search for more companies in CT

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for CuraGen